Vaxil Bio Ltd. shared the results of first preclinical experiment whose purpose was to test the immune response of COVID-19 vaccine candidate. These results provide the first pre-clinical validation of in silico modelling announced a few weeks ago. By leveraging its platform, Vaxil discovered a potential peptide vaccine against COVID-19 back in February 2020 and then proceeded to manufacture these peptides as well as design the preclinical program to prove effectiveness. The first experiment in this Program is now complete. As is common in such early preclinical trials/research programs, the first experiment was performed on healthy donor blood cells to validate the immune response in a screening protocol. It was designed to establish that signal peptides demonstrate a favorable immune response (immunogenicity profile). The results of this test were positive, as proliferation was observed in varying degrees in T cell population (CD3+) as well as in specific subpopulations: cytotoxic T lymphocytes (CD8+) and more prominently in T helper cells (CD4+). The individual peptides, as well as in combination, all responded in varying degrees, more than unstimulated cells. What was most encouraging was that the most pronounced response was in T helper cells (CD4+). These responses are The company is also assessing several large-scale contract manufacturers to develop a scaled GMP process, in the event preclinical experiments continue to generate positive results.